Highmark and Blue KC Get Their Approval, Reshaping the Blues Map as ACA Enrollees Pay the Price for Lapsed Subsidies

Missouri's Department of Commerce and Insurance handed Highmark Inc. and Blue Cross and Blue Shield of Kansas City the regulatory blessing they needed on Tuesday, March 17, clearing the last gate on a three-month-old affiliation that will close March 31 and reshape the Blue Cross Blue Shield map for the first time in a generation. The approved combination, structured as an affiliation rather than an acquisition with no cash changing hands, will place Blue KC under the Highmark Health umbrella while leaving the Kansas City carrier locally governed and locally branded. Together the two non-profits and their health plan affiliates will serve roughly eight million members across Pennsylvania, West Virginia, Delaware, New York and now Missouri, vaulting Highmark past Florida Blue and into position as the third-largest Blues organization in the country, behind only Health Care Service Corp. and Elevance Health.

The deal had been telegraphed since December, when Highmark president and CEO David Holmberg framed it as a path for Blue KC to "accelerate innovation" without losing the local control that Kansas City employers and brokers had spent decades cultivating. What changed this week was the Missouri sign-off, which followed earlier clearances from Pennsylvania and West Virginia regulators and from the Blue Cross Blue Shield Association — the licensing body whose blessing matters because both organizations are independent licensees of the Blues mark. Blue KC president and CEO Erin Stucky told employees the closure would unlock "new technology, capabilities and resources" while keeping its 1,200-employee workforce, its Kansas City headquarters and its existing leadership intact. For Highmark, the affiliation is the fifth state added to its core Blue service area in less than a decade, after the 2013 West Virginia merger with Mountain State Blue Cross Blue Shield and the 2021 acquisition of HealthNow, which brought Western and Northeastern New York into the fold.

What the deal actually changes

For employer groups that buy Blue KC coverage today, the closing date is mostly a non-event in the short run — premium notices, ID cards and provider directories will continue to bear the Blue KC logo. The medium-term implications are more interesting. Highmark has spent the last three years building out enGen, its technology subsidiary that handles claims, member portals and analytics for affiliated plans, and the company has been explicit that enGen will become the back-office platform for Blue KC over a multi-year integration. That migration is the entire point of the deal: by spreading enGen's fixed costs across more lives, Highmark can offer Kansas City employers the kind of digital member experience that previously required a national carrier's scale, and Blue KC can stop trying to fund competing technology investments out of a regional risk pool. The trade-off for self-funded administrative-services-only customers is the question of whether enGen's analytics and reporting will match what Blue KC has historically provided through its own teams; the carrier said early ASO renewal materials will preserve existing reporting through 2027 while migration plans are finalized.

The deal also matters for the broader payer-consolidation conversation that has dominated 2026. Where the for-profit Big Six insurers (UnitedHealth, Elevance, Cigna, Humana, CVS Health/Aetna and Centene) have spent the year focused on Medicare Advantage rationalization, exchange exits and prior-authorization commitments, the not-for-profit Blues are quietly executing on geographic expansion through affiliation rather than M&A. Independence Blue Cross's affiliation with AmeriHealth Caritas, Florida Blue's relationship with GuideWell and the Highmark/Blue KC closing this month all share the same legal architecture: no cash exchange, separate boards, shared technology platform. It is a structure that satisfies state regulators worried about local control while delivering most of the scale benefits of a traditional acquisition, and it has become the dominant template for non-profit Blues consolidation.

ACA enrollees in distress, and a Senate framework that lands without a fix

While the Blues news set the agenda for industry M&A, the week's most important demand-side story was a Kaiser Family Foundation poll released Thursday, March 19, that put numbers on what has been an increasingly visible affordability crisis on the individual exchange. KFF surveyed 1,117 adults in February and early March, including more than 80% of the ACA enrollees the foundation had originally polled in November, and the results were stark. Eighty percent of those who reenrolled for 2026 said their premiums, deductibles or other costs are higher this year than last, with 51% calling them "a lot higher." Seventeen percent of returning enrollees told KFF they were uncertain they could keep paying their premiums for the remainder of the year. About 9% of those originally polled in November reported they had to forgo insurance entirely after the enhanced premium tax credits expired at the end of 2025 — a number that, extrapolated across the 23.1 million enrollment base reported during open enrollment, would translate into roughly two million Americans losing coverage between November and the start of March alone. Among those who switched plans or dropped coverage, 71% told pollsters that the expense was a "major reason" for the change.

The same Thursday brought a political answer of sorts. Twelve Senate Finance Committee Democrats led by Ranking Member Ron Wyden circulated a "Health Coverage That Works for Everyone" framework, the most detailed Democratic policy response since the enhanced PTC negotiations collapsed in February. The three-pillar framework targets affordability through restored advance premium tax credits and expanded eligibility for low-income people in non-expansion states, simplicity through what the senators described as "a one-stop shop" that would consolidate Medicaid, marketplace and Medicare enrollment, and what the framework calls an end to "corporate greed" through new restrictions on junk insurance, surprise tax bills and shrinking provider networks. Senator Mark Warner, a member of the framework group, framed the political argument in a release that morning: enhanced subsidies "weren't a partisan idea — they made coverage affordable for millions of working families, and Republicans let them lapse anyway." The framework does not contain a legislative vehicle, and with the Senate calendar dominated by appropriations into April, no markup has been scheduled. But it gave Finance Democrats their first organized response to the KFF data and the first detailed counter to the CMS proposed 2027 NBPP rule that closed for comment March 13.

A handful of statistics from the new KFF poll sketch the shape of the affordability problem more cleanly than the political framing:

• 80% of returning ACA enrollees say 2026 costs are higher than 2025; 51% say "a lot higher"
• 17% of returning enrollees uncertain they can pay their premiums all year
• 9% of those polled in November have dropped coverage entirely

Medicare freezes new suppliers as Russian-linked Texas fraud unfolds

The CRUSH initiative continued to generate news this week, but the most consequential item was operational rather than regulatory. CMS confirmed the rollout of a six-month nationwide moratorium on enrollment of new DMEPOS medical supply companies, originally announced February 25 and tied directly to an alleged $400 million Medicare fraud scheme that federal prosecutors say was orchestrated by Nika Machutadze, a Russian citizen indicted in the Western District of Texas. According to court filings unsealed in connection with a Texas Department of Insurance investigation, Machutadze used two shell companies — Centurion Superior Medical LLC in Texas and a second entity in Florida — to submit nearly 79,000 Medicare claims, mostly for urinary catheters, in just over a month. Investigators traced at least $988,830 in proceeds wired to a Hong Kong account before the indictment was filed.

The moratorium, which CMS may extend in six-month increments, applies to new enrollment applications and does not affect medical supply companies already enrolled in Medicare. The agency simultaneously released a request for information under its Comprehensive Regulations to Uncover Suspicious Healthcare initiative — CRUSH — asking states, providers, suppliers, payers and technology companies how the agency should integrate AI into provider screening, expand surety bond requirements and re-validate "high-risk providers" more frequently. Public comments on the CRUSH RFI are due March 30, and major associations including the American Hospital Association, the National Association of Medicaid Directors and America's Essential Hospitals all signaled this week they would be filing detailed responses. The House Energy and Commerce Subcommittee on Oversight gave the initiative a public airing on Tuesday, March 17, when CMS Deputy Administrator and Chief Operating Officer Kimberly Brandt testified about the agency's effort to shift from a "pay-and-chase" enforcement model to "front-end fraud prevention" using machine-learning algorithms, fingerprinting, background checks and unannounced site visits. The hearing's most notable subplot was Subcommittee Chair John Joyce (R-Pa.) and Representative Kevin Mullin (D-Calif.) pressing Brandt about the agency's investigation of alleged Medicare hospice and home-health fraud in California — an investigation that CMS Administrator Mehmet Oz publicly tied to "$3.5 billion in Los Angeles County" alone in a press appearance Thursday, March 19, drawing a sharp rebuttal from California state officials whose own data, they said, showed the state outperforming most others in fraud recovery.

Prior authorization commitment shows real numbers

The carrier-side commitment to standardize prior authorization, announced last summer with HHS and CMS, produced its first detailed progress reports this week. Cigna told reporters that it expects to standardize more than 70% of its prior authorization volume for medical services by the end of 2026 and has already cut its medical-PA volume by about 15%. Aetna disclosed that it has now standardized 88% of its prior authorization volume and continues to maintain the fewest medical services requiring prior authorization among national health plans. UnitedHealthcare went further: the carrier reiterated commitments to eliminate prior authorization for an additional 30% of services by year-end, including select outpatient surgeries, certain diagnostic tests like echocardiograms, and a list of outpatient therapies and chiropractic services that the company will publish on UHCProvider.com before the changes take effect. The company also said roughly 92% of UnitedHealthcare prior-authorization requests are now approved in less than 24 hours and that prior authorization is required for only 2% of its medical services overall.

Roughly 50 health plans have signed onto the broader industry commitment, including all six of the largest publicly-traded conglomerates: Elevance Health, Centene, Cigna, CVS Health/Aetna, Humana and UnitedHealthcare. Their stated goal is a common framework for both payers and providers by January 1, 2027, with a focus on electronic-only submission, gold-card programs that exempt high-performing providers from authorization for high-volume services, and a single national clinical-criteria library that providers can query before they submit. The progress is real, but so is the gap: the AHA and AMA filings on the CRUSH RFI both noted that volume reductions have been heavily concentrated in low-stakes services and that the procedures most likely to delay care — inpatient admissions, oncology infusions, advanced imaging — remain almost universally subject to authorization. The Washington Post Intelligence Service published a March 17 investigation into the WISeR pilot, the CMS Innovation Center model that began January 15 in New Jersey, Ohio, Oklahoma, Texas, Arizona and Washington, finding that AI-driven prior-authorization decisions in traditional Medicare have already produced documented care delays for patients in all six states. The pilot runs through 2031, and the Post reporting kicked off a fresh round of physician-society letters questioning whether the WISeR design — AI denial first, human clinician review second — meets the statutory standard for traditional Medicare coverage determinations.

State action: Wisconsin closes the 12-month postpartum gap

State policy delivered one of the week's quieter but most consequential stories. On Wednesday, March 18, Wisconsin Governor Tony Evers signed Wisconsin Act 102, the bill that extends BadgerCare postpartum Medicaid coverage from 60 days to a full 12 months, effective July 1, 2026. The legislation, sponsored in the Assembly by Representative Lisa Subeck, passed the Wisconsin Senate unanimously and the Assembly 95-1, an unusual show of bipartisan unity in a state legislature that had blocked similar bills in three previous sessions. With the signing, Arkansas becomes the only state in the country that has not extended postpartum Medicaid coverage to 12 months, a remarkable run for a policy that the Center for Children and Families at Georgetown described as a "fully funded national consensus" four years after the American Rescue Plan first authorized the option.

The same week, the Holland & Knight Health Dose flagged a series of related federal moves: the CMS Innovation Center's MAHA ELEVATE Model opened applications for a voluntary functional and lifestyle medicine pilot in traditional Medicare, with a letter-of-intent deadline of April 10 and a planned launch in October 2026; CMS rolled out enhanced identity verification on Medicare.gov using CLEAR, ID.me and Login.gov; and the Senate Finance Committee Democrats sent letters to 11 pharmaceutical manufacturers requesting details on most-favored-nation pricing agreements ahead of the third negotiation cycle, where all 15 selected manufacturers have now confirmed participation. CMS will send proposed maximum fair prices to those manufacturers by June 1, with negotiations concluding November 1. None of those items will dominate a quarterly board meeting, but together they sketch the unusual breadth of federal activity squeezed into a single week — and the way the CRUSH initiative, the WISeR pilot, the NBPP 2027 rulemaking and the state-level Medicaid expansion are all converging on the same set of questions about who pays, who decides, and how much the system can change without breaking what works.

What it adds up to

The Highmark/Blue KC closing matters because it shows what consolidation looks like in the part of the market the for-profit Big Six do not dominate. The KFF poll matters because it puts hard numbers on a consumer-affordability crisis that the policy debate has been treating in the abstract since the enhanced PTC expired. The Senate Democrats' framework matters because it gives the affordability conversation a structured policy spine even without a legislative vehicle. The Wisconsin postpartum bill matters because it closes a 49-state-and-Washington-D.C. consensus that the only remaining holdout is Arkansas. And the DMEPOS moratorium, the WISeR investigation and the prior-authorization progress reports matter because they show federal payer policy moving on three tracks simultaneously — fraud enforcement, AI-driven utilization management, and industry self-regulation — each producing real operational consequences for hospitals, insurers and the millions of Americans whose care touches all three.

The single throughline this week is that the system is still capable of moving in multiple directions at once: the Blues map is being redrawn through cooperative affiliation, the marketplace is shedding enrollees as costs rise, federal agencies are simultaneously cracking down on fraud and pushing AI into coverage decisions, and individual states are still finding bipartisan room to expand a program everyone says is under stress. None of those stories cancels out the others. All of them will be on the desk of the same brokers, employer benefits leaders and individual buyers who have to make 2027 decisions starting in May.